Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 56 entries
View as:

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04816669 Org: User:
Start: 04/01/21 End: 12/02/21 Due: 12/02/22

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT05310084 Org: User:
Start: 04/20/22 End: 10/05/22 Due: 10/05/23

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04455620 Org: User:
Start: 01/26/21 End: 05/28/24 Due: 05/28/25

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05547464 Org: User:
Start: 07/31/23 End: 05/31/27 Due: 05/31/28

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

Phase: N/A Priority: Normal
NCT ID: NCT04588480 Org: User:
Start: 10/21/20 End: 11/25/21 Due: 11/25/22

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

Phase: N/A Priority: Normal
NCT ID: NCT06469164 Org: User:
Start: 07/01/24 End: 08/31/25 Due: 08/31/26

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

Phase: N/A Priority: Normal
NCT ID: NCT04895982 Org: User:
Start: 10/15/21 End: 07/23/23 Due: 07/23/24

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05537038 Org: User:
Start: 04/18/23 End: 01/31/26 Due: 01/31/27

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Phase: N/A Priority: Normal
NCT ID: NCT04382898 Org: User:
Start: 12/19/19 End: 01/23/24 Due: 01/23/25

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04486378 Org: User:
Start: 03/08/21 End: 08/31/30 Due: 08/31/31

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT05988203 Org: User:
Start: 09/21/23 End: 03/31/26 Due: 03/31/27

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04710043 Org: User:
Start: 06/08/21 End: 09/30/25 Due: 09/30/26

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06892548 Org: User:
Start: 05/02/25 End: 06/30/31 Due: 06/30/32

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

Phase: N/A Priority: Normal
NCT ID: NCT05596734 Org: User:
Start: 10/28/22 End: 12/28/23 Due: 12/28/24

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04813627 Org: User:
Start: 07/02/21 End: 04/30/26 Due: 04/30/27

RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID

Phase: N/A Priority: Normal
NCT ID: NCT02316457 Org: User:
Start: 10/31/16 End: 05/17/23 Due: 05/17/24

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06069778 Org: User:
Start: 03/27/24 End: 09/18/24 Due: 09/18/25

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Phase: N/A Priority: Normal
NCT ID: NCT05581641 Org: User:
Start: 12/15/22 End: 09/06/24 Due: 09/06/25

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT04816643 Org: User:
Start: 03/24/21 End: 12/08/23 Due: 12/08/24

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02410733 Org: User:
Start: 03/31/15 End: 06/20/23 Due: 06/20/24

Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06712316 Org: User:
Start: 01/07/25 End: 12/31/30 Due: 12/31/31

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06449209 Org: User:
Start: 08/05/24 End: 05/31/28 Due: 05/31/29

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05262530 Org: User:
Start: 03/28/22 End: 12/31/25 Due: 12/31/26

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05004181 Org: User:
Start: 08/25/21 End: 10/04/23 Due: 10/04/24

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT05543616 Org: User:
Start: 09/23/22 End: 08/11/25 Due: 08/11/26